Abstract Treatment resistance affects 20–60% of patients with psychiatric disorders; and is
associated with increased healthcare burden and costs up to ten-fold higher relative to …

Antipsychotic drugs are central to the treatment of schizophrenia and other psychotic
disorders but are ineffective for some patients and associated with side-effects and …

Outcomes of psychotic disorders are associated with high personal, familiar, societal and
clinical burden. There is thus an urgent clinical and societal need for improving those …

Abstract Treatment-resistant schizophrenia (TRS), the persistence of positive symptoms
despite≥ 2 trials of adequate dose and duration of antipsychotic medication with …

BackgroundTreatment-resistant schizophrenia (TRS) is associated with high levels of
functional impairment, healthcare usage and societal costs. Cross-sectional studies may …

Abstract Treatment-resistant schizophrenia (TRS) will affect about one in three patients with
schizophrenia. Clozapine is the only treatment approved for TRS, and patients should be …

Treatment-resistant schizophrenia (TRS) occurs in approximately 30% of individuals
diagnosed with schizophrenia. The identification and management of TRS in clinical …

BackgroundRemission and recovery rates for people with first-episode psychosis (FEP)
remain uncertain. AimsTo assess pooled prevalence rates of remission and recovery in FEP …

Schizophrenia remains a major health burden, highlighting the need for new treatment
approaches. We consider the potential for targeting the trace amine (TA) system. We first …

Synaptic dysfunction is hypothesised to play a key role in schizophrenia pathogenesis, but
this has not been tested directly in vivo. Here, we investigated synaptic vesicle glycoprotein …